Oncology Learning Network

Verified
Online/Digital
Oncology Learning Network® is an online resource for the latest developments in oncology practice, providing a customized experience for readers to stay informed about the topics that matter most to them. Through clinical insights, peer-reviewed journal articles, interactive features, research news updates, accredited continuing educational programs, and professional live meetings and events, Oncology Learning Network serves as a collaborative learning and networking environment for a multidisciplinary community of oncology medical professionals. As the digital home to the respected and well-known online and live continuing education programs in oncology provided by Imedex and NACCME, Oncology Learning Network allows busy oncology providers to meet all of their educational and informational needs in one place. Source

Actions

Share this page

Media Outlet details

Scope International, Trade/B2B
Language English
Country United States of America
Similarweb UVMSimilarweb UVM Request pricing
Comscore UVMComscore UVM Request pricing

Recent Articles

Search

Tucatinib Demonstrates Consistent Benefit Across First-Line HER2-Positive Metastatic Breast Cancer Populations

|
By Erika P. Hamilton
| Oncology Learning Network Verified
Clinical Summary: Design/Population: Subgroup analyses from the phase 3 HER2CLIMB-05 trial evaluated tucatinib added to trastuzumab and pertuzumab maintenance therapy in patients with previously untreated HER2-positive metastatic breast cancer. Analyses examined outcomes according to hormone receptor status, presence of brain metastases, and de novo versus recurrent metastatic disease.
Open in Who Shared Issue with article?

Selinexor Plus Ruxolitinib as a Frontline Combination in Patients With Myelofibrosis

|
By Claire Harrison
| Oncology Learning Network Verified
Clinical Summary: Design/Population: The phase 3 SENTRY trial randomized JAK inhibitor–naïve patients with intermediate-1–risk or higher myelofibrosis to receive selinexor plus ruxolitinib or placebo plus ruxolitinib in a double-blind, placebo-controlled study. Key Outcomes: Selinexor plus ruxolitinib significantly improved spleen volume responses compared with ruxolitinib alone and was associated with an early overall survival benefit.
Open in Who Shared Issue with article?

First-in-Class Mutant CALR Antibody Demonstrates Durable Clinical Activity in Myelofibrosis

|
By Claire Harrison
| Oncology Learning Network Verified
Clinical Summary: Design/Population: The phase 1 INCA033989-101 and INCA033989-102 studies evaluated the mutant CALR-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients with CALR-mutant myelofibrosis who were JAK inhibitor–intolerant, relapsed or refractory, ineligible for JAK inhibitor therapy, or had a suboptimal response to ruxolitinib.
Open in Who Shared Issue with article?

Concurrent Thoracic Radiotherapy, Platinum/Etoposide Chemotherapy, and Durvalumab Immunotherapy Does Not Improve Outcomes in Extensive-Stage Small Cell Lung Cancer

| Oncology Learning Network Verified
Clinical Summary: Design/Population: This phase 3 randomized trial evaluated the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung cancer. The study planned to enroll approximately 302 patients but was stopped early because of safety concerns and a preplanned interim analysis showing no evidence of survival benefit.
Open in Who Shared Issue with article?

Health-Related Quality of Life Preserved with Neoadjuvant and Adjuvant Enfortumab Vedotin plus Pembrolizumab in Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer

| Oncology Learning Network Verified
Clinical Summary: Design/Population: The phase 3 KEYNOTE-905 trial evaluated perioperative enfortumab vedotin plus pembrolizumab (neoadjuvant followed by adjuvant therapy) versus radical cystectomy alone in patients with muscle-invasive bladder cancer who were cisplatin-ineligible or declined cisplatin.
Open in Who Shared Issue with article?

Osimertinib Plus Selumetinib Shows Limited Activity Following First-Line Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer

|
By Emily Estrada Verified
| Oncology Learning Network Verified
Clinical Summary: Design/Population: A phase 2 module of the ORCHARD platform study evaluated osimertinib plus selumetinib in patients with EGFR-mutated advanced non-small cell lung cancer harboring BRAF alterations following disease progression on first-line osimertinib. Key Outcomes: The combination demonstrated minimal clinical activity, with a low objective response rate, and short median progression-free survival.
Open in Who Shared Issue with article?

Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma

|
By Emily Estrada Verified
| Oncology Learning Network Verified
Clinical Summary: Design/Population: This investigator-initiated phase 2 trial evaluated camrelizumab plus apatinib in patients with refractory chordoma. Key Outcomes: The combination demonstrated encouraging response rates, prolonged progression-free survival, and durable response with manageable toxicity. CDKN2A alterations were associated with poorer outcomes.
Open in Who Shared Issue with article?

How I Treat: Advanced Prostate Cancer

| Oncology Learning Network Verified
AMP_PAGE_VIEWPending Maximum Storage Duration: SessionType: HTML Local Storage AMP_remote_config_090786228dPending Maximum Storage Duration: PersistentType: HTML Local Storage AMP_SR_START_090786228d_1780812854728Pending Maximum Storage Duration: PersistentType: HTML Local Storage AMP_SR_START_090786228d_1780812929532Pending Maximum Storage Duration: PersistentType: HTML Local Storage AMP_URL_INFOPending Maximum Storage Duration: SessionType: HTML Local Storage EXP_090786228dPending Maximum...
Open in Who Shared Issue with article?

How I Treat: Pancreatic Ductal Adenocarcinoma

| Oncology Learning Network Verified
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma. According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
Open in Who Shared Issue with article?

Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas

|
By Stephanie Holland
| Oncology Learning Network Verified
Clinical Summary: Design/Population: This long-term follow-up assessed outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphomas treated with a single infusion of the CD19-directed CAR T-cell therapy tisagenlecleucel. Key Outcomes: No relapses occurred beyond 5.4 years, with durable lymphoma-free survival observed at 10 years. Long-term remissions were associated with persistent CAR T-cell activity, and late toxicities were uncommon.
Open in Who Shared Issue with article?

Oncology Learning Network Journalists

Holland, Stephanie
Rosania, Kara